Lifecore Biomedical’s (LFCR) “Equal Weight” Rating Reaffirmed at Stephens

Stephens reiterated their equal weight rating on shares of Lifecore Biomedical (NASDAQ:LFCR) in a research note published on Friday,Benzinga reports. They currently have a $6.00 price target on the stock.

Separately, Craig Hallum boosted their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 22nd.

Lifecore Biomedical Stock Performance

NASDAQ:LFCR opened at $7.62 on Friday. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83. Lifecore Biomedical has a 52-week low of $3.68 and a 52-week high of $8.90. The firm has a market cap of $280.62 million, a price-to-earnings ratio of 95.25 and a beta of 0.98. The business’s fifty day moving average is $7.03 and its 200 day moving average is $5.80.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. Research analysts predict that Lifecore Biomedical will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Lifecore Biomedical

A number of hedge funds and other institutional investors have recently modified their holdings of LFCR. Marshall Wace LLP boosted its holdings in shares of Lifecore Biomedical by 87.3% in the 2nd quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock worth $1,540,000 after purchasing an additional 139,887 shares in the last quarter. 272 Capital LP boosted its holdings in Lifecore Biomedical by 511.1% during the 3rd quarter. 272 Capital LP now owns 143,480 shares of the company’s stock valued at $707,000 after acquiring an additional 120,002 shares during the period. Bank of New York Mellon Corp purchased a new stake in Lifecore Biomedical during the 2nd quarter valued at about $327,000. Geode Capital Management LLC boosted its holdings in Lifecore Biomedical by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock valued at $2,948,000 after acquiring an additional 55,703 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in Lifecore Biomedical by 2,640.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock valued at $268,000 after acquiring an additional 52,414 shares during the period. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.